MONOAMINE OXIDASE INHIBITOR (MAOI)
Zelapar is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat motor symptoms in people with Parkinson’s disease. Zelapar may be prescribed as a monotherapy to people with early Parkinson’s disease, or as an adjunctive (add-on) treatment in those who are taking levodopa/carbidopa and experiencing reductions in its effectiveness. Zelapar may be referred to by its drug name, selegiline. Selegiline is also sold under the brand name Eldepryl.
Zelapar is a member of a class of antidepressant drugs called monoamine oxidase inhibitors (MAOIs). In cases of Parkinson’s disease, Zelapar is believed to work by preventing the breakdown of dopamine in the brain, thereby increasing the amount of dopamine available.
Some medications are available both as generic and branded products. Although generic and branded formulations of a drug contain the same active ingredients at the same concentrations, your body may react differently to different formulations. Check with your doctor before switching between drug brands or between generic and branded drugs.
How do I take it?
Zelapar is taken orally as a disintegrating tablet once daily.
Common side effects of Zelapar include drowsiness, dizziness, dry mouth, nausea, vomiting, stomach pain, gas, constipation, trouble sleeping, unusual dreams, back or leg pain, or rash. If you are taking Zelapar disintegrating tablets, you may develop mouth sores. Tell your doctor if these side effects become worse.
Rare but serious side effects may include falling asleep during daily activities, abnormally low blood pressure, impulse control disorders, hallucinations, and unusual shaking or body movements,
For more details about this treatment, visit:
Zelapar — Drugs
Zelapar — RxList
We never share your personal information with anyone.
Want to stay up to date on the latest news and articles about Parkinson's disease?